Group 1 - The core viewpoint is that Hong Kong's innovative drug concept stocks are becoming increasingly active, with significant gains in the net value of related ETFs [2] - As of July 18, the top ten passive index funds by weekly growth include various innovative drug ETFs, all showing over 13% increase [3] - The top-performing fund, Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drug ETF Link A Fund, achieved a weekly growth of 13.98% [3] Group 2 - The Invesco Great Wall CSI Hong Kong Stock Connect Innovative Drug ETF Link Fund was established on March 14, 2025, with a net asset value of approximately 493 million yuan as of the end of Q2 [4] - The fund has underperformed its benchmark by 4.76 percentage points since inception but outperformed it by 3.69 percentage points in Q2 [4] - The only healthcare ETF among the top funds is the Fortune Heng Seng Hong Kong Stock Connect Healthcare ETF, which has underperformed its benchmark by 0.76 percentage points since inception and by 7.43 percentage points over the past year [5]